Comparative Evaluation of Regulatory Registration & Approval Pathways for Semaglutide 14 mg Tablet in Emerging South American Markets: Chile, Peru and Bolivia
Abstract
The regulatory registration and approval processes for semaglutide tablets 14 mg in Chile, Peru, and Bolivia—three developing South American markets—are compared in this paper. Regulatory bodies, dossier specifications, submission processes, review schedules, labelling requirements, and post-approval variances are all examined in the analysis. The results show that the three nations' technical documentation, GMP certification standards, language requirements, and approval procedures differ from one another. Bolivia retains a more administrative and mostly offline submission method, whereas Chile and Peru adhere to more structured regulatory frameworks with components that are in line with international norms. In order to facilitate effective market entrance planning and compliance in developing South American pharmaceutical markets, this comparison offers key regulatory insights.
Conclusion: The investigation reveals significant variation in Chile, Peru & Bolivia s Semaglutide market Regulatory Frameworks, particularly with regard to documentation, submission process & Compliance Bolivia has a more Manual Method Whereas Chile and Peru adhere to more Standarized, globally aligned systems. For an efficient registration Strategy and seamless market entry, these distinctions are essential.
Downloads
References
https://www.grandviewresearch.com/industry-analysis/semaglutide-market-report
2. Business Research company. Semaglutides Market Share Analysis and Forecast To 2035 [Internet]. UK: Business research Company; 2026 March [cited 2026 Jan 15]. Available from:
https://www.thebusinessresearchcompany.com/report/semaglutides-global-market-report
3. Data insights market. Semaglutide Oral Tablets Strategic Insights: Analysis 2026 and Forecasts 2034 [Internet. US: Data insights market; 2026 March 20 [cited 2026 jan 15]. Available from:
https://www.datainsightsmarket.com/reports/semaglutide-oral-tablets-329545
4. NIDDK. Type 2 Diabetes - NIDDK [Internet]. India: Niddk Type-2 Diabetes; 2017 May [cited 2026 Jan 15]. Available from:
https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/type-2-diabetes
5. Diabetes.org. Understanding Type 2 Diabetes [Internet]. USA: Understanding Type-2 Diabetes; 2025 May [cited 2026 Jan 15]. Available from:
https://diabetes.org/about-diabetes/type-2
6. WebMD. Type 2 Diabetes Causes and Risk Factors [ Internet]. USA: Type 2 Diabetes Causes and Risk Factors; 2024 August 16 [cited 2026 Jan 15]. Available from: https://www.webmd.com/diabetes/diabetes-causes
7. Mayo Clinic. Type 2 diabetes - Symptoms and causes [Internet]. US: Mayoclinic Type-2 Diabetes; 2025 Jan 27 [cited 2026 Feb 15]. Available from:
https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193
8. Healthline. Signs and Symptoms of Type 2 Diabetes [Internet] India: Healthline; 2025 June 30 [cited 2026 Jan 15]. Available from:
https://www.healthline.com/health/diabetes/early-warning-signs-type-2-diabetes
9. MacariusHealth. Rybelsus 14mg Tablet - 14mg Novo Nordisk India Pvt Ltd [ Internet]. India: Macraioushealth; 2025 Sep [cited 2026 Jan 15]. Available from: https://macariushealth.com/products/diabetes-endocrinology/rybelsus-14mg-tablet-14-mg/
10. Diabetes.org. Understanding Type 2 Diabetes [Internet]. USA: Understanding Type-2 Diabetes; 2025 May [cited 2026 Jan 15]. Available from:
https://diabetes.org/about-diabetes/type-2
11. Mayo Clinic. Semaglutide (oral route) - Side effects & dosage [Internet]. US: Mayoclinic; 2026 March 01 [cited 2026 Jan 15]. Available from:
https://www.mayoclinic.org/drugs-supplements/semaglutide-oral-route/description/drg-20492085
12. 1mg. Ozempic 1mg Injection: View Uses, Side Effects, Price and Substitutes [Internet]. India: 1 mg Injection of Ozempic; 2026 [cited 2026 Jan 15]. Available from:
https://www.1mg.com/drugs/ozempic-1mg-injection-1089012
13. Clevel and Clinic. Semaglutide (Ozempic): How It Works & Side Effects [Internet]. India: Semaglutide work and side effects; 2025 March [cited 2026 Jan 15]. Available from:
https://my.clevelandclinic.org/health/drugs/19011-semaglutide-injection
14. Go Drug Bank. Semaglutide [Internet]. India: Semaglutide Drug Profile; 2025 March [cited 2026 jan 15]. Available from: https://go.drugbank.com/drugs/DB13928
15. PubChem. Semaglutide [Internet]. USA: Semaglutide; 2024 May [cited 2026 Jan 15]. Available from:
https://pubchem.ncbi.nlm.nih.gov/compound/56843331
16. Novo Nordisk Canada Inc. RYBELSUS® (semaglutide tablets) Product Monograph Health Professional Information and Scientific Information [Internet]. USA: Monograph RYBELUS; 2024 March [ cited 2026 Jan 16]. Available from:
https://pdf.hres.ca/dpd_pm/00055582.PDF
17. (FDA). label submitted by Novo Nordisk Inc. RYBELSUS® (semaglutide) Prescribing Information [Internet]. USA: FDA Label Submitted by Novo Nordisk; 2017 [cited 2025 Jan 15]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf
18. Ispch. Public Health Institute Chile Registration [Internet]. Chile: Ispch gob; 2025 March 12 [cited 2026 Jan 15]. Available from:
https://www.ispch.gob.cl/anamed/medicamentos/registro-sanitario-de-productos-farmaceuticos/
19. gob.pe. Gob pe Institucion [Internet]. Peru: Gob Pe Institucion; 2009 November 25 [cited 2026 Jan 15]. Available from:
https://www.gob.pe/institucion/congreso-de-la-republica/normas-legales/2813441-29459?
20. 20. Digemid. Supreme Decree No. 016-2011/SA – DIGEMID [Internet]. Peru: Supreme Decree No. 016-2011/SA; 2011 July 27 [cited 2026 Jan 15]. Available from:
https://www.digemid.minsa.gob.pe/webDigemid/normas-legales/2011/decreto-supremo-no-016-2011-sa/
21. DIGEMID. COMUNICADO N° 050-2023. [ Internet]. Peru: Sanitary Registration of Pharmaceutical Product; 2023 October [cited 2026 Jan 15]. Available from:
https://www.digemid.minsa.gob.pe/webDigemid/comunicados/2023/comunicado-n-050-
22. AGEMED. Historical Overview [Internet]. Bolivia: Historical Overview AGEMED; 2024 [cited 2026 Jan 15]. Available from:
https://www.agemed.gob.bo/#nuestra_institucion/resena_historica
23. AGEMED. Pharmaceutical Regulation [Internet]. Bolivia: Pharmaceutical Noms of Bolivia; 2025 March [cited 2026 Jan 15]. Available from:
https://www.agemed.gob.bo/#regulacion/normas_nacionales
24. Agemed. Ministerio de Salud y Deportes – Estado Plurinational de Bolivia. Medicamentos seguros, eficaces y de calidad [Internet]. Bolivia: Manual for Drug Registration Bolivia; 2003 September [cited 2026 Jan 15]. Available from:
www.agemed.gob.bo/reg-far/doc_reg_far/T-N-11-RM-0909-RSANITARIO.pdf
25. Tech publish. Global Pharmaceutical Regulatory Authorities and Guidelines Database – tech-publish [Internet]. USA: Global Pharmaceutical Regulatory Authorities and Guidelines Database; 2025 October 26 [cited 2026 Jan16]. Available from:
https://tech-publish.com/global-pharmaceutical-regulatory-authorities-and-guidelines-database/?
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
